BioSpace News Archive

Pharm Country

Merck’s COVID-19 Pill Up for Panel Review as Scientists Voice Concerns

Merck is getting its chance at participating in the pandemic. The FDA has announced an outside expert panel will meet on November 30 to deliberate on Merck’s COVID-19 pill.

October 15, 2021
·
3 min read
·
Kate Goodwin
PharmaDrug Announces Positive Research Results for Cepharanthine in the Treatment of Multiple Cancers When Used Alone and in Combination with Chemotherapy

Cepharanthine reproducibly demonstrates potential as a monotherapy in treating multiple cancers with unsatisfactory treatment options.

October 15, 2021
·
13 min read
Hope Alights at ECTIRMS 2021 as Companies Present New Data

The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ran from October 13 to 15, with companies globally presenting cutting-edge studies on MS.

October 15, 2021
·
4 min read
·
Mark Terry
BioForest

Clinical Catch-Up: October 11-15

It was yet another busy week for clinical trial announcements. Take a look.

October 15, 2021
·
11 min read
·
Mark Terry
Policy

FDA Action Alert: Omeros, Oyster Point, BeiGene and Ocular

The U.S. Food and Drug Administration has a few PDUFA dates on its calendar for this week. Here’s a look.

October 15, 2021
·
3 min read
·
Mark Terry
Business

Illumina Makes First Imprint on GRAIL with New CEO

Genomics veteran Bob Ragusa is taking over GRAIL, a newly-acquired business unit of Illumina, Inc. He is taking over as CEO Hans Bishop steps down from his role.

October 15, 2021
·
2 min read
·
Alex Keown
Drug Development

ICYMI: Biopharma News You Might Have Missed This Week

Read about TFF Pharmaceuticals and Augmenta Bioworks’ dry powder COVID-19 antibody formula, the world’s first gene editing clinical trial for PKU, Bayer’s COVID-19 vaccine and other key developments in life sciences research.

October 15, 2021
·
6 min read
·
Vanessa Doctor, RN
Drug Development

Moderna Panel Vote Near Carbon Copy of Pfizer’s

The news of a unanimous decision by the adcom came just two days after the agency issued a 45-page document that contained vague comments on the drug.

October 15, 2021
·
2 min read
·
Vanessa Doctor, RN
Policy

J&J Launches Talc Subsidiary to Take Brunt of Liability

Facing thousands of lawsuits related to its talc-based products, life sciences giant Johnson & Johnson is launching a separate subsidiary dubbed LTL Management LLC that will take the brunt of potential legal liabilities.

October 15, 2021
·
3 min read
·
Alex Keown
Policy

FDA Panel Unanimously Recommends J&J Booster Shot

The advisory committee voted 19-0 to recommend the extra dose of the J&J shot for anyone 18 years and older.

October 15, 2021
·
2 min read
·
Mark Terry